Neuestes
Moderna, Merck MRNA-Krebspanzerkrankung erreicht wichtige Meilenstein in der Studie zu Melanom
Die kombinierte Therapie zeigt erste Erfolge in späten Stadien für den personalisierten mRNA-Krebsimpfstoff und treibt die Aktien von Moderna um 150% in die Höhe. Die Patentsperre für Keytruda nähert sich, da die Wettbewerber darum ringen, die Ergebnisse nachzuahmen.
US equities mixed; SMI edges lower as oil hits four-week high
Futures on the Dow slipped 0.13% while Nasdaq futures rose 0.1% ahead of U.S. open. Brent crude surged 2.6% to $94.04/bbl, nearing $100/bbl. Swiss Re and Logitech led SMI laggards.
Aminex unit issues dispute notice over Tanzania gas project delays
Ndovu Resources alleges operator ARA Petroleum breached obligations under the 2026 work program for the Ntorya Gas Development, triggering a 90-day dispute resolution window.
U.S. national debt tops $40 trillion as servicing costs near $1.4 trillion
Crossing the $40 trillion mark, the U.S. faces rising debt servicing expenses and elevated Treasury yields, with projections pointing to $50 trillion by 2029. Market intervention has done little to curb structural pressures.
Apollo Global discloses data breach amid broader cyberattack wave
Asset manager confirms unauthorized access to cloud platforms last month; investigation ongoing as hackers target financial firms with low-tech tactics.
Die Bank of America warnt vor Auswirkungen auf den Markt, falls der US-Anleiheplan scheitert
Der BofA-Stratege Hartnett sieht eine Schwäche des Dollars und zunehmende Kurzpositionen in Risikogewchten, wenn die 30-Jahres-Zinssätze der US-Staatsanleihen bei über 5% bleiben. Der S&P 500 verliert 1,9% aufgrund der Volatilität der Anleihemärkte.
LSI Industries CFO to retire in August 2027 after decade-long tenure
James E. Galeese, CFO since 2017, will step down after over 10 years with the Cincinnati-based lighting and display manufacturer. The company plans to name a successor by mid-2027.
D.E. Shaw discloses $1B+ stake in Sysco amid AI push
Hedge fund D.E. Shaw reveals a more than $1 billion stake in Sysco, as the food distributor accelerates AI-driven efficiency gains and eyes a major acquisition. Sysco’s stock has underperformed over the past year.
AI fintech Tabs raises $92M, valued at $400M amid revenue surge
Tabs, an AI-driven finance automation platform, has grown from a 2023 launch to 180 employees and triple-digit revenue growth, backed by $92M in funding and a $400M valuation.
Michelin shares rise 1.7% after JPMorgan upgrade to Overweight
Stock climbs to €34.68 as JPMorgan lifts price target to €42, citing accelerating truck tire demand and durable growth in high-tech composites.
Die Terminierung der BOJ-Sitzung im Juli 2027 verleiht Spekulationen über den Zeitpunkt einer Zinserhöhung zusätzliche Dynamik
Die nächste Policy-Sitzung der Bank of Japan, die für den 21. und 22. Juli 2027 geplant ist, fällt mit dem Ende der Amtszeit von zwei strikten Mitgliedern des Rates zusammen, was Fragen zur Normalisierungsstrategie der Zentralbank aufwirft.
Euronext wheat hits four-week high as Black Sea disruptions curb exports
Benchmark wheat prices surged 1.8% to €241 per metric ton on Euronext amid escalating war-related shipping disruptions in the Black Sea, redirecting demand to Western Europe.
J&T Express posts 124% profit surge as non-China revenue hits 50%
First-half profit more than doubled to $350.6 million on a 39.5% revenue rise, with half of sales now generated outside China. The express delivery group raised 2026 capex guidance to $800-900 million.
Gold steigt, als Trump Wirtschaftssanktionen gegen Iran ankündigt
US-Sanktionsdrohung gegen Iran treibt Gold- und Ölpreise in die Höhe; Fed-Rate-Schritte bleiben vor Jackson Hole gering.
Ultragenyx surges 11% after FDA approval of gene therapy for rare disease
Ultragenyx shares jumped 11.1% in pre-market trading after the FDA granted accelerated approval for GENGLYCOS, the company's first gene therapy. Analysts raised price targets to as high as $58.
Target’s grocery push drives traffic growth, but broader shopper appeal remains key
Food and beverage sales rose 7% in the latest quarter as Target expands private-label offerings, yet grocery still accounts for less than a quarter of total merchandise sales.
U.S. Treasury's Bessent to outline Iran sanctions plan on Monday
Secretary Scott Bessent will detail planned measures against Iran and Treasury bond buybacks at a press conference. Bond yields surged before partially reversing after Wednesday's support announcement.
Robo.ai to release H1 2026 results Sunday after restructuring
The Abu Dhabi-based AI firm will file unaudited financials with the SEC on Sunday, following the disposal of legacy operations and acquisition of Neurovia AI and Quantum Core Capital.
Hays profit rises 3% in FY26 as £50m cost cuts offset fee decline
Pre-exceptional operating profit increased to £48.6m despite an 8% drop in net fees to £905.5m, as restructuring delivered £50m in annualized savings ahead of schedule.
Swiss Prime Site posts 5.1% EPS growth, portfolio value tops CHF 14bn
H1 2026 results show funds from operations per share at CHF 2.15, with full-year guidance raised to the upper end of CHF 4.25-4.30. Asset management AuM rose to CHF 14.8bn.
Swiss Market Index slips 0.26% as Logitech, Swiss Re lead declines
Logitech and Swiss Re shares drop nearly 3% each as SMI falls 0.26%, while Aryzta hits multi-year low after UBS downgrade. Oil near $94, Brent nears $100 as inflation concerns resurface.
Euro Stoxx 50 falls as yields, oil rise; Swiss SMI supported by China trade deal
Eurozone blue-chip index down 0.35% as bond yields climb and crude oil advances; Swiss SMI pares losses to 0.13% on China trade pact. JD Sports drops 14% on weak outlook; Eni, BP gain on higher oil.
Die Schweiz und China bringen den Handelsabkommen finalisiert, um fast alle Zölle auf Schweizer Ausfuhren abzuschaffen
Das aktualisierte Abkommen senkt die Zölle auf 99,8% der schweizerischen Waren nach China, darunter Uhren, Arzneimittel und Maschinen, mit jährlichen Einsparungen von 244 Millionen Franken.
Basilea shares hit eight-year high after strong H1 results
Swiss biopharma firm’s stock surges 3% to CHF 64.30 as first-half revenue beats expectations, driven by Cresemba’s global uptake. Patent cliff looms from late 2027.